🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. CISPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., PACLITAXEL, anti-NKG2A mAb, CARBOPLATIN, PEMETREXED DISODIUM

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. CISPLATINE VIATRIS 25 mg/25 ml, solution à diluer pour perfusion, Tecentriq 1 200 mg concentrate for solution for infusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Paclitaxel Accord Healthcare 6 mg/ml solution à diluer pour perfusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    The George Institute

    Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.

    phase 2 small molecule active

    1 trial

  3. CISPLATINO SANDOZ, LIBTAYO 350 mg concentrate for solution for infusion.

    Fondazione Telethon ETS

    locally advanced cervical carcinoma

    phase 2 small molecule active

    1 trial

  4. CLAIRYG 50 mg/ml, solution pour perfusion, MESNA EG 100 mg/ml, solution injectable pour perfusion, CYCLOPHOSPHAMIDE SANDOZ 1000 mg, poudre pour solution injectable ou pour perfusion, SOLUMEDROL 1 g, poudre et solvant pour solution injectable

    Pari Pharma GmbH

    paraneoplastic sensory neuropathy with anti-Hu antibodies

    phase 2 small molecule active

    1 trial

  5. CRIZOTINIB, CRIZOTINIB, XALKORI 200 mg hard capsules, CRIZOTINIB, CRIZOTINIB, CRIZOTINIB, XALKORI 250 mg hard capsules, Torisel 30 mg concentrate and solvent for solution for infusion

    Disc Medicine

    Neuroblastoma (NBL), Rhabdomyosarcoma (RMS), Inflammatory Myofibroblastic Tumors (IMT), Other ALK/ROS1/MET-positive malignancies, Anaplastic Large Cell Lymphoma (ALCL)

    phase 2 small molecule active

    1 trial

  6. CYCLOPHOSPHAMIDE MONOHYDRATE, VINORELBINE, Tecentriq 840 mg concentrate for solution for infusion

    Istituto Gentili S.r.l.

    Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens

    phase 2 small molecule active

    1 trial

  7. CYCLOPHOSPHAMIDE, Paclitaxel 6 mg/mL concentrate for solution for infusion, Doxorubicin 2 mg/ml Concentrate for Solution for Infusion, DURVALUMAB, Oleclumab_IJB2

    The George Institute

    Luminal B Breast Cancer

    phase 2 small molecule active

    1 trial

  8. Cabazitaxel Accord 20 mg/ml concentrate for solution for infusion, Lutathera 370 MBq/mL solution for infusion, Xofigo 1100 kBq/mL solution for injection, Lynparza 150 mg film-coated tablets, Docetaxel Aurovitas 20 mg/ml concentrado para solución para perfusión, BAY 1841788

    Ningbo Cancer Hospital

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  9. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, PACLITAXEL, TOPOTECAN, farletuzumab ecteribulin

    Bristol-Myers Squibb Australia Pty Ltd

    Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    phase 2 small molecule active

    1 trial

  10. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, TRABECTEDIN

    Fondazione Telethon ETS

    recurrent ovarian cancer

    phase 2 small molecule active

    1 trial

  11. Calcio levofolinato Teva Generics 175 mg polvere per soluzione per infusione, BEVACIZUMAB , ZALTRAP 25 mg/ml concentrate for solution for infusion, Oxaliplatin 5 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, FLUOROURACIL , FLUOROURACIL , Irinotecan Accord 20 mg/ml concentrato per soluzione per infusione, CAPECITABINE

    Fondazione Telethon ETS

    Patients with metastatic colorectal cancer (mCRC) RAS-mutant

    phase 2 small molecule active

    1 trial

  12. Calcium Folinate 10 mg/ml Solution for injection or infusion, Irinotecanhydrochloridetrihydraat Hikma 20 mg/ml, concentraat voor oplossing voor infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Avastin 25 mg/ml concentrate for solution for infusion., Oxaliplatin Eugia 5 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Patients with colorectal peritoneal metastases with a PCI-score of 1-20

    phase 2 small molecule active

    1 trial

  13. Calquence 100 mg hard capsules, IMBRUVICA 420 mg film-coated tablets, IMBRUVICA 140 mg hard capsules, IMBRUVICA 140 mg hard capsules, BRUKINSA 80 mg hard capsules, Lisaftoclax, Calquence 100 mg hard capsules, MabThera 500 mg concentrate for solution for infusion, Lisaftoclax, Lisaftoclax

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

    phase 2 small molecule active

    1 trial

  14. Capecitabina KERN PHARMA 150 mg comprimidos recubiertos con película EFG, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Irinotecán Hospira 20 mg/mL concentrado para solución para perfusión EFG., Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Capecitabina

    The George Institute

    Localised Colon Cancer (stage II-III)

    phase 2 small molecule active

    1 trial

  15. Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, Doce onkovis 20 mg/ ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., Pemetrexed medac 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Vinorelbin onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed medac 100 mg Pulver für ein Konzentrat zur Herst

    Ningbo Cancer Hospital

    Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)

    phase 2 small molecule active

    1 trial

  16. Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Avastin 25 mg/ml concentrate for solution for infusion., Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion.

    TESARO Bio Netherlands B.V.

    Ovarian Neoplasms

    phase 2 small molecule active

    1 trial

  17. Carboplatin 10 mg/ml Concentrate for Solution for Infusion, DOMVANALIMAB, Paclitaxel 6 mg/ml concentrate for solution for infusion, Zimberelimab

    Gilead Sciences Pty Limited

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  18. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, JNJ-61186372, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  19. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion, volrustomig, Cyramza 10 mg/ml concentrate for solution for infusion

    AstraZeneca AB

    Solid Tumors, SQ, NSQ NSCLC

    phase 2 small molecule active

    1 trial

  20. Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Alectinib (Alecensa), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concent

    Hoffmann-La Roche

    Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  21. Carboplatino Hikma 10 mg/ml soluzione per infusione, Avastin 25 mg/ml concentrate for solution for infusion., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Tumours, Gynecological

    phase 2 small molecule active

    1 trial

  22. Cemiplimab 350 MG Intravenous Solution

    Regeneron UK Limited

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  23. Cemiplimab and Fianlimab - 1, Fianlimab, Cemiplimab & Fianlimab - 2, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  24. Cemiplimab and Fianlimab - 1, Placebo, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, CARBOPLATIN, CISPLATIN, Cemiplimab & Fianlimab - 2, PACLITAXEL

    Lacuna Pharma Pty Ltd

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources